Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental lymphoma drug DS-3201b enters early human testing

NCT ID NCT02732275

Ongoing Disease control Sponsor: Daiichi Sankyo Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests an experimental drug called DS-3201b in about 100 adults with non-Hodgkin lymphoma whose cancer has come back or is not responding to current treatments. The main goals are to find a safe dose and see how the drug works in the body. The study also checks for side effects and looks at how well the drug might shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADULT T-CELL LEUKEMIA/LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adult T-cell leukemia/lymphoma B-cell neoplasm Leukemia-Lymphoma, Adult T-Cell lymphoma mature T-cell and NK-cell non-Hodgkin lymphoma non-Hodgkin lymphoma primary cutaneous T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA, MALIGNANT NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

  • City of Hope National Medical center

    Duarte, California, 91010, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

  • Emory University

    Atlanta, Georgia, 30322, United States

  • Hackensack University Medical Center

    Hackensack, New Jersey, 07601, United States

  • Imamura General Hospital

    Kagoshima, Kagoshima-ken, 890-0064, Japan

  • Iwate Medical University Hospital

    Morioka, Iwate, 020-8505, Japan

  • Kagoshima University Hospital

    Kagoshima, Kagoshima-ken, 890-8520, Japan

  • Kumamoto University Hosipital

    Kumamoto, Kumamoto, 860-8556, Japan

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Nagasaki University Hospital

    Nagasaki, Nagasaki, 852-8501, Japan

  • Nagoya City University Hospital

    Nagoya, Aichi-ken, 467-8602, Japan

  • National Cancer Center Hospital

    Chūōku, Toyko, 104-0045, Japan

  • National Cancer Center Hospital East

    Kahiwa-shi, Chiba, 277-8577, Japan

  • The Institute of Medical Science, The University of Tokyo

    Minato-ku, Tokyo, 108-8639, Japan

  • The Ohio State University Wexner Medical Center and James Cancer Hospital

    Columbus, Ohio, 43210, United States

  • Thomas Jefferson University

    Philadelphia, Pennsylvania, 19107, United States

  • University of the Ryukyus Hospital

    Nakagami-gun, Okinawa, 903-0215, Japan

  • Weill Cornell Medicine

    New York, New York, 10021, United States

  • Yale University

    New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.